Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · Real-Time Price · USD

1.370

+0.020 (1.48%)

At close: Mar 6, 2026, 4:00 PM EST

1.420

+0.050 (3.65%)

After-hours: Mar 6, 2026, 7:17 PM EST

Pyxis Oncology Employees

Pyxis Oncology had 44 employees as of December 31, 2024. The number of employees decreased by 6 or -12.00% compared to the previous year.

Employees

44

Change (1Y)

-6

Growth (1Y)

-12.00%

Revenue / Employee

$64,091

Profits / Employee

-$2,206,500

Market Cap

85.30M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	44	-6	-12.00%
Dec 31, 2023	50	-25	-33.33%
Dec 31, 2022	75	19	33.93%
Dec 31, 2021	56	-	-

Related Stocks

Company Name	Employees
Champions Oncology	213
Pliant Therapeutics	171
Seres Therapeutics	103
PolyPid	73
Verrica Pharmaceuticals	71
aTyr Pharma	65
PMV Pharmaceuticals	47
Cognition Therapeutics	28

Employee Rankings

PYXS News

4 weeks ago - Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity - GlobeNewsWire
2 months ago - Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
2 months ago - Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript - Seeking Alpha
2 months ago - Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewsWire
4 months ago - Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
4 months ago - Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
5 months ago - Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings - GlobeNewsWire
5 months ago - Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - GlobeNewsWire